Percutaneous Closure of Patent Foramen Ovale for Cryptogenic Stroke: The Issue is Finally Settled

Antonis S Manolis


Based on newer data from randomized controlled trials and meta-analyses, the previously controversial and highly debated issue of patent foramen ovale (PFO) closure in patients with cryptogenic stroke is finally settled in favor of closure over medical therapy for the secondary prevention of cryptogenic stroke attributable to paradoxical embolism. One PFO closure device finally received FDA approval in October 2016. Rhythmos 2017; 12(4):60-62.


cryptogenic stroke; paradoxical embolism; patent foramen ovale; percutaneous closure

Full Text:



  • There are currently no refbacks.